Source: West J Med
1991 Feb;154(2):186-197.
Author: Black KL;Mazziotta JC;Becker DP PubMed ID: 1848735
Abstract:
Recent advances in experimental tumor biology are being applied to
critical clinical problems of primary brain tumors. The expression of
peripheral benzodiazepine receptors, which are sparse in normal brain,
is increased as much as 20-fold in brain tumors. Experimental studies
show promise in using labeled ligands to these receptors to identify the
outer margins of malignant brain tumors. Whereas positron emission
tomography has improved the dynamic understanding of tumors, the labeled
selective tumor receptors with positron emitters will enhance the
ability to specifically diagnose and greatly aid in the pretreatment
planning for tumors. Modulation of these receptors will also affect
tumor growth and metabolism. Novel methods to deliver antitumor agents
to the brain and new approaches using biologic response modifiers also
hold promise to further improve the management of brain tumors